- >> Quote Page >>
- >> Company & Fund Search Results >>
- >> Companies A-Z >>
- >> Market News >>
- >> Heatmaps >>
- >> Director Deals >>
- >> Broker Views >>
- >> Market Diary >>
- >> Stock Screener >>
- >> Charts >>
- >> Market Info >>
- >> Fund Centre >>
- >> Fund Screener >>
- >> Fund Details Page >>
- >> Modules - Chart Page >>
- >> Modules - Home Page 'Latest' Panel >>
- >> Modules - Sectors >>
| Bid Price | 227.00 | High Price | 232.00 |
|---|---|---|---|
| Ask Price | 228.00 | Low Price | 225.00 |
| Open Price | 232.00 | Spread | 0.44% |
| Prev Close | 228.00 | Volume | 203,305 |
Syncona Share Price
Intraday
Historic - 6 months
Syncona Share Price Information
| Name | Syncona |
|---|---|
| Epic | SYNC |
| Sector | Equity Investment Instruments |
| ISIN | GG00B8P59C08 |
| Activites | Syncona Limited (formerly BACIT Limited) is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Its vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. |
| Index | FTSE 250 |
| Latest Share Price (p) | 228.00 | Net Gearing (%) | 1.61 |
|---|---|---|---|
| Market Capitalisation (£m) | 1,536.39 | Gross Gearing (%) | 1.62 |
| Shares in issue (m) | 663.67 | Debt Ratio | 0.74 |
| P/E Ratio | 224.76 | Debt-to-Equity Ratio | 0.45 |
| Total dividends per share (p) | 2.30 | Assets / Equity Ratio | 1.02 |
| Dividend Yield (%) | 0.00 | Price to book value | 1.06 |
| Dividend Cover | 0.45 | ROCE (%) | 15.01 |
| Earning per share (p) | 1.03 | EPS Growth (%) | 32.05 |
| 52-week high / low (p) | 306.50 / 212.00 | DPS Growth (%) | 0.00 |
Syncona Broker Views
| Date | Broker | Recommendation | Price | Old Target Price | New Target Price | Notes |
|---|---|---|---|---|---|---|
| 03 Jun | Numis | Buy | 225.75 | 320.00 | - | Reiterates |
| 01 May | Numis | Buy | 225.75 | 320.00 | - | Reiterates |
| 17 Apr | Northland Capital | Corporate | 225.75 | - | - | Retains |
| 16 Apr | Northland Capital | Corporate | 225.75 | - | - | Retains |
| 05 Apr | Northland Capital | Corporate | 225.75 | - | - | Retains |
Syncona Director Deals
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 27 Mar 2019 | Nicholas Moss | Buy | 8,004 @ 249.70p | £19,985.99 |
| 20 Mar 2019 | Ellen Strahlman | Buy | 45,185 @ 244.19p | £110,337.25 |
| 19 Mar 2019 | Gian Piero Reverberi | Buy | 16,000 @ 253.40p | £40,544.00 |
| 19 Mar 2019 | Robert Hutchinson | Buy | 19,775 @ 251.00p | £49,635.25 |
| 30 Jul 2018 | Jeremy Tigue | Buy | 4,504 @ 241.80p | £10,890.67 |
Syncona News
-
Syncona valuation falls in June quarter despite asset sales
Mon 12 Aug 2019 07:11
-
Syncona completes sale of Blue Earth Diagnostics for $476.3m
Thu 01 Aug 2019 09:38
-
Syncona sells Blue Earth Diagnostics for $450m
Thu 27 Jun 2019 08:51
-
Syncona appoints Melanie Gee as chair-designate
Tue 04 Jun 2019 07:22
-
UK stocks track sideways; Ryanair descends
Mon 20 May 2019 09:02
Data provided by 
and 
Prices quoted have a delay of at least 15 minutes. You may receive a different price (which may be higher or lower) when an instruction is executed. Though all reasonable efforts are made to present accurate data, Equiniti Financial Services Limited and third party data providers accept no responsibility for the correctness, completeness or accuracy of the data provided.
Where past performance details are included this is not a reliable indicator of future performance. Short-term past performance of less than one year is a particularly unreliable indicator.
and Prices quoted have a delay of at least 15 minutes. You may receive a different price (which may be higher or lower) when an instruction is executed. Though all reasonable efforts are made to present accurate data, Equiniti Financial Services Limited and third party data providers accept no responsibility for the correctness, completeness or accuracy of the data provided.
Where past performance details are included this is not a reliable indicator of future performance. Short-term past performance of less than one year is a particularly unreliable indicator.